The study will test an investigational product called VCN-01 in patients with metastatic pancreatic cancer. “Investigational” means that VCN-01 has not been approved by the U.S. Food and Drug Administration (FDA) to treat any disease.

VCN-01 will be administered in combination with two standard-of-care chemotherapy drugs called nab-paclitaxel and gemcitabine. The goals of the study are to evaluate the safety and tolerability of VCN-01 and to determine whether co-administration of VCN-01 can improve treatment outcomes in metastatic pancreatic cancer patients treated with nab-paclitaxel and gemcitabine.
   
This clinical study consists of 2 arms. Participants will be randomly assigned to one of the following arms:

• Arm 1: Receives Nab-paclitaxel and gemcitabine as standard of care. Patients in this arm will not receive VCN-01.
• Arm 2: A maximum of two doses of VCN-01 administrated in combination with nab-paclitaxel and gemcitabine standard of care.   

Total participation will last for approximately for 2 years.